Viromed H1 FY26 net loss widens to €1.1 million; revenue rises 4.17% to €2.5 million

Bitget2026/09/28 10:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Viromed Medical posted H1 2026 revenue of €2.5 million, up 4.17% from a year earlier.
Net loss widened to €1.1 million from €0.8 million a year earlier.
Equity climbed 43.9% to €9.5 million, lifting the equity ratio to 67.6% from 39.9%.
Management attributed the earnings trend to expenses for the PulmoPlas study and ViroCAP med approval and launch.
Confirmed full-year 2026 guidance for a significant increase in revenue and net income; ViroCAP med sales started in July.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viromed Medical AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2406298_en) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Viromed H1 FY26 net loss widens to €1.1 million; revenue rises 4.17% to €2.5 million

You may also like

Crypto prices